NCT02965677Unknown不适用
Evaluation of the Safety and Efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter （LEGFLOW）in Treatment of Stenosis or Occlusion in Femoral-popliteal Arteries：A Prospective, Multicenter, Randomized, Controlled Clinical Study
ZhuHai Cardionovum Medical Device Co., Ltd.13 个研究点 分布在 1 个国家目标入组 172 人开始时间: 2016年12月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 172
- 试验地点
- 13
- 主要终点
- clinically driven target lesion revascularization (CD-TLR)
研究概览
简要总结
To evaluate the safety and efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW) compared with the standard balloon (Admiral Xtreme) for the treatment of stenosis or occlusions in femoral popliteal artery.
详细描述
To evaluate the safety and efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW) compared with the standard balloon (Admiral Xtreme) for the treatment of stenosis or occlusions in femoral popliteal artery.
This is a prospective, multicenter, prior desiged, randomize and controlled study, planned to enrol 172 subjects. all these subjects will be allocated 1:1 to the LEGFLOW OTW group n=86 and Admiral Xtreme group n=86. and accept the treatment of LEGFLOW and Admiral Xtreme balloon. and followed up at day 0-30, month 6, 12 by DUS and clinical examination. all the endpoint data will be assessed by DUS core-lab, CEC, then be statisticed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years and ≤ 85 years.
- •De novo or restenotic lesions in the femoral popliteal artery due to atherosclerosis, which located in the superficial femoral artery and/or proximal popliteal artery (arterial segment starting at least 1cm beyond the common femoral artery bifurcation to the distal P1 segment of the popliteal artery at the level of the proximal edge of the patella). And the patients are suitable for endovascular therapy with LEGFLOW OTW or Admiral Xtreme.
- •Rutherford class 2 to
- •Target lesion length ≤ 200mm.
- •Target lesion stenosis ≥ 70% or total occlusion, and it can be passed with common manipulation.
- •Reference vessel diameter ≥ 4mm and ≤ 8mm by visual estimate.
- •Target lesion consists of a single of de novo or restenotic lesion, or a adjacent lesion or a combination lesion or multiple lesion which meets the following criteria:
- •adjacent lesion: (1) lesion space ≤ 30mm; (2) total lesion length (include lesion space) ≤ 200mm; (3) can be treated as a single lesion.
- •Combination lesion: combination lesion is defined as not a chronic total occlusion (CTO), but may include a part of total occlusion (100% stenosis). The total lesion length ≤ 200mm.
- •Multiple lesion: (1) lesion space > 30mm; (2) total lesion length (include lesion space) ≤ 200mm; (3) can be treated as multiple lesions.
- •Angiographic evidence of adequate distal run-off to the foot (at least one native calf vessel is patent, defined as < 50% diameter stenosis), whether or not this outfolw was re-established by previous intervention.
- •If subject has ipsilateral/contralateral iliac disease that requires treatment during the procedure, the iliac lesions must meet all the following criteria:
- •Iliac lesion or occlusion is ≤ 100mm in length;
- •must be treated before the target lesion (superficial femoral artery/proximal popliteal artery).
- •must be successfully treated before target lesion treatment; success is defined as: (1) residual stenosis < 30%; (2) free of dissection which can limit blood flow; (3) no occurrence of thrombus, embolization, or other SAE.
- •Life expectancy more than one year.
- •Understands the study objective and is willing to participate and provide the informed consent form, and is willing to comply with specified follow-up evaluations at the specified time points.
排除标准
- •Women of childbearing age with negative pregnancy test before procedure, and breastfeeding women.
- •Stroke or STEMI within 30 days prior to the procedure.
- •Either local or systemic thrombolytic therapy within 6 weeks prior to the procedure.
- •Any major surgical operation (operation class ≥ 3) or interventional therapy within 30 days prior to the procedure.
- •Any major selective surgical operation (operation class ≥ 3) or interventional therapy within 30 days prior to the procedure.
- •Restenotic lesions after DCB or bypass surgery.
- •Target limb has been previously treated with bypass surgery.
- •Guidewire must be passed through from the distal part of limb.
- •Known allergies or sensitivities to contrast agent, paclitaxel, anti-platelet, anticoagulants or thrombolytic drugs.
- •Known allergies or sensitivities to heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II.
- •Aneurysm located at the target vessel.
- •Acute or sub-acute thrombosis in the target vessel.
- •Angiographic evidence of severe calcification (defined as dense circumferential calcification that makes the target lesion non-dilatable and/or calcificatin that is present on both sides of the vessel wall and that extends more than 5 cntinuous centimeters in length within the target lesion prior to contrast injection or digital subtraction angiography).
- •The bilateral lower limb must be treated in one procedure.
- •Uncorrected bleeding disorder.
- •Renal insufficiency (serum creatinine >2.5mg/dL or renal dialysis).
- •Stenosis or occlusions due to non-atherosclerosis, such as thrombotic occlusive vasculitis or vasculitis.
- •Septicemia or bacteremia.
- •Patients with severe disease (such as severe chronic obstructive pulmonary disease, malignant tumor, dementia, etc.) or patient's physical condition may affect the compliance with this study.
- •Pre-dilation resulted in a major (≥ Grade D) flow-limiting dissection or residual stenosis > 70%.
- •Major distal amputation (above the transmetatarsal) in the study limb or non-study limb.
- •Patients who have participated in another investigational drug or device trial that has not completed the primary endpoint.
研究组 & 干预措施
LEGFLOW OTW group
Experimental
in this group subject will be treated by Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW) and followed up
干预措施: Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (Device)
Admiral Xtreme
Active Comparator
in this group subject will be treated by Peripheral Balloon Dilatation Catheter (Admiral Xtreme) and followed up
干预措施: Peripheral Balloon Dilatation Catheter (Device)
结局指标
主要结局
clinically driven target lesion revascularization (CD-TLR)
时间窗: 12 month post procedure
次要结局
- Procedural Success(at 0-30 days)
- Device Success(at 0-30 days)
- Change in Rutherford classification measured(at 0-30 days, 6 months and 12 months post procedure)
- Change in ABI measure(at 0-30 days, 6 months and 12 months post procedure)
- Walking capacity assessment by Walking Impairment Questionnaire (WIQ)(at 0-30 days, 6 months and 12 months post procedure)
- Target limb amputation rates(at 0-30 days, 6 months and 12 months post procedure)
- Major Adverse Event (MAE) rate which including all cause death, CD-TLR and major target limb amputation.(at 0-30 days, 6 months and 12 months post procedure)
- Clinical-driven target vessel revascularization (CD-TVR) rates(at 0-30 days, 6 months and 12 months post procedure)
- Walking distance assessment by Six Minute Walk Test (6MWT)(0-30 days, 6 months and 12 months post procedure compared with baseline)
- Clinical Success(at 0-30 days)
- Target vessel revascularization (TVR)(at 0-30 days, 6 months and 12 months post procedure)
- Clinical-driven target lesion revascularization (CD-TLR) rates(at 0-30 days, 6 months and 12 months post procedure)
- Quality of life assessment by EQ5D(at 0-30 days, 6 months and 12 months post procedure compared with baseline)
- Target lesion revascularization (TLR)(0-30 days, 6 months and 12 months post procedure)
- Thrombus at the target lesion site(0-30 days, 6 months and 12 months post procedure)
研究者
研究点 (13)
Loading locations...
相似试验
Unknown
不适用
A Study of Below The Knee Arteries' Stenosis or Occlusion Treated With LEGFLOW OTWPeripheral Artery DiseaseNCT02962232ZhuHai Cardionovum Medical Device Co., Ltd.172
已完成
不适用
A Study of Hemodialysis Arteriovenous Fistulae Stenosis Treated With APERTOPeripheral Arterial DiseaseFistulaNCT02962141ZhuHai Cardionovum Medical Device Co., Ltd.161
Unknown
4 期
Efficacy and Safety of Paclitaxel-eluting Balloon for Treatment of Lesions in Native Small Coronary ArteriesCoronary Artery DiseaseNCT01903902Gachon University Gil Medical Center1,000
已完成
不适用
Paclitaxel Releasing Balloon in Patients Presenting With In-Stent RestenosisIn-stent Coronary Artery RestenosisNCT00961181Biotronik AG81
已完成
不适用
Clinical Post Market Clinical Follow-up (PMCF) on Peripheral Arteries Treated With SeQuent® Please Over The Wire (OTW)Peripheral Arterial Occlusive DiseaseNCT02460042B. Braun Melsungen AG960